1. ACT-1 A PROSPECTIVE MULTICENTER PHASE I/IIA STUDY OF PREOPERATIVE NEOADJUVANT BEVACIZUMAB FOR NEWLY DIAGNOSED GLIOBLASTOMA. (3rd December 2022) Authors: Tanaka, Toshihide; Tamura, Ryota; Takei, Jun; Morimoto, Yukina; Teshigawara, Akihiko; Tohmoto, Kyoichi; Kuranari, Yuki; Imai, Ryotarou; Yamamoto, Yohei; Hasegawa, Yuzuru; Akasaki, Yasuharu; Murayama, Yuichi; Miyake, Keisuke; Sasaki, Hikaru Journal: Neuro-oncology advances Issue: Volume 4(2022)Supplement 3 Page Start: iii7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. ANGI-1 Impact of neoadjuvant bevacizumab on transcriptional factor for stemness, macrophage polarization, and oxygenation of tumor microenvironment in glioblastoma. (6th December 2021) Authors: Tanaka, Toshihide; Takei, Jun; Teshigawara, Akihiko; Tohmoto, Kyoichi; Yamamoto, Yohei; Hasegawa, Yuzuru; Tamura, Ryouta; Sasaki, Hikaru; Akasaki, Yasuharu; Murayama, Yuichi Journal: Neuro-oncology advances Issue: Volume 3(2021)Supplement 6 Page Start: vi1 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗